REGENXBIO Inc, a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of...
Singapore –Cobra Biologics, an international contract development and manufacturing organization (CDMO) ...
Santhera Pharmaceuticals which is Swiss specialty pharmaceutical company focused on the development and commercializatio...
An investment firm focused on the North American manufacturing sector, Altus Capital Partners has announced that it has ...
Synthego, the leading provider of genome engineering products, and Eurofins Genomics, a global leader in bioanalytical t...
Singapore - Mylan N.V. announced that its U.S. based Mylan Pharmaceuticals business is conducting a voluntary nationwide...
Eureka Therapeutics has announced publication in Cell Discovery validating its ARTEMIS antibody-TCR (AbTC...
Notable leadership change comes as Brickell prepares to progress its lead product candidate, sofpironium bromide, to Pha...
Researchers at the National Centre for Complementary and Integrative Health (NCCIH), part of the National Institutes of ...
Images from the world's first full-body 3D medical scanner named EXPLORER have been released. This scanner is developed ...
Danish dermatology specialists LEO Pharma and California based company PellePharm has announced a strategic development ...
The development of new medical products that are considered the highest priority for people in developing countries is h...
With the new parallel imaging method CAIPIRINHA, Mark Griswold, Peter Jakob and their colleagues have taken the technolo...
US based clinical-stage biotechnology company Magenta Therapeutics has announced that it has strengthened its executive ...
In order to scale up prevention and treatment, and increased investment, to protect vulnerable people from Malaria, WHO ...
LimaCorporate is pleased to announce that Michel Orsinger, Board Member of LimaCorporate's Advisory Board, will ass...
Sandoz, a Novartis division, and Pear Therapeutics, Inc., has announced the commercial launch of reSET for patients with...
Merck and Pfizer Inc. announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combinatio...
